Suggestions
Richard Kurtz
Corporate Business Development, Board Member, Strategic Advisor
Richard Kurtz is a seasoned life sciences executive with extensive experience in global product management, marketing, and corporate business development.1 He currently serves as a Board Member at Genetic Analysis AS, a company focused on developing diagnostic solutions.23
Professional Background
Current Role: Richard Kurtz is the Vice President of Corporate Business Development at Bio-Rad Laboratories, a position he has held since April 2022.14 In this role, he leads corporate business development, executing mergers and acquisitions (M&A) and strategic investments in Life Science Research and Clinical Diagnostics.1
Previous Positions at Bio-Rad Laboratories: Kurtz has a long history with Bio-Rad Laboratories, having held several key positions:
- Senior Director, Corporate Business Development (March 2021 - April 2022)
- Director, Corporate Strategy (January 2015 - March 2021)
- Marketing Director, Gene Expression Division (January 2012 - December 2014)
- Senior Product Manager / Product Manager (January 2006 - March 2008)
- Genomics FAS Manager (January 2005 - January 2006)1
Education
Richard Kurtz holds a Ph.D., which he obtained between 1996 and 2001, likely in Molecular Biology or a related field.5
Board Memberships
In addition to his role at Genetic Analysis AS, Kurtz serves on the boards of several other organizations:
- Stealth Mode Startup Biotech (developing a high-throughput single-cell antibody discovery platform)
- Protein Dynamic Solutions Inc. (developing a platform for therapeutic protein characterization and testing)
- aLight Sciences (developing a single-molecule detection platform for proteins and nucleic acids)
- EvoNexus (a technology incubator for California's startup and entrepreneurial community)1
Richard Kurtz's diverse experience in life sciences, particularly in business development, product management, and marketing, along with his board memberships in various biotech startups, makes him a valuable asset to Genetic Analysis AS's board of directors.